CNS Pharmaceuticals (CNSP) Change in Account Payables (2018 - 2023)

CNS Pharmaceuticals (CNSP) has 6 years of Change in Account Payables data on file, last reported at $790034.0 in Q2 2023.

• Quarterly Change in Account Payables rose 67424.27% year-over-year to $790034.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $2.3 million (up 430.96% YoY) and the FY2022 annual result came in at $1.7 million, up 64.28% from the prior year.
• Change in Account Payables improved to $790034.0 in Q2 2023, from -$901296.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q4 2022 to a low of -$901296.0 in Q1 2023.
• A 5-year average of $187333.9 and a median of $57775.5 in 2019 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables tumbled 697.79% — and 2023, when it soared 67424.27%.
• Tracing CNSP's Change in Account Payables over 5 years: stood at -$105231.0 in 2019, then soared by 761.54% to $696149.0 in 2020, then declined by 25.32% to $519871.0 in 2021, then surged by 326.69% to $2.2 million in 2022, then plunged by 64.38% to $790034.0 in 2023.
• The last three Change in Account Payables figures came in at $790034.0 (Q2 2023), -$901296.0 (Q1 2023), and $2.2 million (Q4 2022), per Business Quant data.